Lucentis (Ranibizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Lucentis (Ranibizumab) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth in the historic period can be attributed to the growing prevalence of age-related macular degeneration (AMD), approval and reimbursement by regulatory authorities, demonstrated efficacy and clinical outcomes, strong brand recognition, and physician adoption of Lucentis. The emergence of biosimilars and increased cost competition also played a significant role in driving market expansion.

Market growth during the forecast period can be attributed to the increasing incidence of diabetic retinopathy (DR) and diabetic macular edema (DME), advancements in treatment protocols and combination therapies, and the aging population contributing to a rising prevalence of retinal diseases. Additionally, expanding market access in emerging markets, ongoing clinical research, and the potential for new indications will boost growth. Major trends in the forecast period include a shift toward longer-interval dosing and maintenance treatment, growing adoption of biosimilars and alternative treatments, the rise of personalized medicine approaches for retinal diseases, increased demand in emerging markets due to improving healthcare access, and the integration of digital health solutions in treatment monitoring.

The rising prevalence of eye-related disorders is expected to drive the growth of the lucentis (ranibizumab) market. Eye-related disorders encompass various conditions that impair the proper functioning of the eyes, and their prevalence is increasing due to factors such as aging, genetic predisposition, lifestyle choices like smoking and poor diet, and environmental influences such as prolonged sun exposure and excessive digital screen use. Lucentis works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for abnormal blood vessel growth and leakage in the retina, common causes of conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). According to the National Eye Institute, 2.2 million Americans will be blind by 2030, indicating a growing need for treatments like Lucentis. Thus, the rising prevalence of eye-related disorders is driving the market for lucentis.

The rise in healthcare spending is a key factor propelling the growth of the lucentis (ranibizumab) market. Healthcare spending, which includes financial resources allocated by individuals, governments, and insurers for healthcare services and products, is increasing due to factors like an aging population, advancements in medical technology, and the rising prevalence of chronic diseases. This growth in healthcare expenditure helps to ensure that treatments like Lucentis are accessible, enabling widespread use in treating retinal diseases such as AMD and DME. It also supports the reimbursement, coverage, and distribution of the drug, ultimately improving patient outcomes and reducing the long-term burden of vision loss. For instance, healthcare spending in the UK increased by 5.6% in 2023, reflecting a larger trend of rising healthcare investments that support the lucentis market.

A key trend in the lucentis (ranibizumab) market is the development of biosimilars to offer more affordable alternatives to the branded product. Biosimilars are biologic medical products that are highly similar to an already approved reference biologic in terms of structure, efficacy, and safety, with no clinically meaningful differences. For example, in April 2024, Formycon AG and Bioeq AG launched FYB201, a biosimilar version of Lucentis, in Canada and Switzerland. Known as Ranopto and Ranivisio in these markets, respectively, the biosimilar provides a more cost-effective option for patients suffering from retinal diseases. Like Lucentis, FYB201 inhibits VEGF-A, a protein that causes abnormal blood vessel growth in the retina, leading to conditions like swelling and vision impairment. The approval and launch of such biosimilars contribute to market growth by expanding access to treatment.

Major players operating in the lucentis (ranibizumab) market are F.Hoffmann-La Roche Ltd, Novartis AG.

North America was the largest region in the lucentis (ranibizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lucentis (ranibizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lucentis (ranibizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lucentis (ranibizumab) is a prescription medication used to treat eye disorders involving abnormal blood vessel growth in the retina, including conditions such as age-related macular degeneration and diabetic retinopathy. It is a recombinant monoclonal antibody fragment designed to inhibit vascular endothelial growth factor (VEGF), a protein that promotes abnormal blood vessel formation in the retina.

The primary types in the lucentis (ranibizumab) market are the single-use prefilled syringe and the single-use glass vial. The single-use prefilled syringe is a device prefilled with a precise dose of the medication, ready for immediate use, allowing for more convenient and accurate administration. Key applications of Lucentis include age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, myopic choroidal neovascularization, and uveitis. The end-users of Lucentis are primarily hospitals, clinics, ambulatory surgical centers, and other healthcare settings.

The lucentis (ranibizumab) market research report is one of a series of new reports that provides lucentis (ranibizumab) market statistics, including lucentis (ranibizumab) industry global market size, regional shares, competitors with a lucentis (ranibizumab) market share, detailed lucentis (ranibizumab) market segments, market trends, and opportunities, and any further data you may need to thrive in the lucentis (ranibizumab) industry. This lucentis (ranibizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lucentis (ranibizumab) market consists of sales of lucentis intravitreal injection and lucentis for biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.